Compare STIM & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STIM | STRO |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.5M | 94.9M |
| IPO Year | 2018 | 2018 |
| Metric | STIM | STRO |
|---|---|---|
| Price | $1.43 | $9.92 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 7 |
| Target Price | $7.00 | ★ $19.67 |
| AVG Volume (30 Days) | ★ 1.3M | 112.9K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $129,873,000.00 | $105,646,000.00 |
| Revenue This Year | $101.67 | $62.61 |
| Revenue Next Year | $10.87 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 78.61 | N/A |
| 52 Week Low | $1.23 | $5.23 |
| 52 Week High | $5.92 | $21.50 |
| Indicator | STIM | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 40.71 | 78.91 |
| Support Level | $1.28 | $9.53 |
| Resistance Level | $1.79 | $10.10 |
| Average True Range (ATR) | 0.15 | 0.93 |
| MACD | 0.06 | 0.15 |
| Stochastic Oscillator | 28.57 | 98.52 |
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.